Complete response rate was 37%, and post-hoc end point of objective response rate was 89%. HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent ...
In the article that accompanies this editorial, Wong et al 18 demonstrate significant clinical activity with tolerable toxicities of the second-generation oncolytic virus vusolimogene oderparepvec ...
TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, ...
A fourth of patients with advanced, anti-PD-1-resistant melanoma responded to the viral mimetic BO-112 plus pembrolizumab. Responses were durable with over half of responding patients alive at 24 ...
RFA and anti-PD-1 combination therapy suppresses abscopal HCC tumors and prevents recurrence in mice
Hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, remains a leading cause of cancer-related mortality worldwide. Although radiofrequency ablation (RFA) is the first-line ...
Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not. In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results